Some do, and the best-performing drug in the comparison is not a GLP-1. A network meta-analysis pooled 13 randomized trials and 3,871 patients with MASLD and F1-F3 fibrosis across 12 interventions [1]. Six beat placebo for resolving the disease without worsening fibrosis: two resmetirom doses, survodutide 6 mg, and tirzepatide at 5, 10 and 15 mg.
Read that as a category rather than a ranking, because the risk ratios run from 2.56 to 7.25 and the intervals span an order of magnitude — survodutide’s alone runs from 2.07 to 25.36. Which of the six is best is not established by numbers that wide.
The trial that carries the most weight for semaglutide specifically ran at 2.4 mg for 72 weeks [2], which is a dose and a duration worth reading as a price rather than a protocol. What 72 weeks at the top of the ladder costs is the part of that result a seller will not quote.
Two economic papers frame why anyone is treating this at all. Diagnosed MASLD in people with type 2 diabetes carried a real annual cost burden in a US cohort [3]. A cost-utility analysis across six countries then found that biopsy-led screening strategies lost to doing nothing [4]. An expensive silent condition with no cost-effective screening route is the setting these drugs arrived into.
Liver disease is the area where these drugs face genuine competition from a different mechanism entirely, and this analysis puts them side by side. The way to read it is categorical rather than ordinal. The cost side of MASH treatment is in what a fatty liver costs a year.
Six interventions separated from placebo. Resmetirom, which is not a GLP-1 drug at all but a thyroid hormone receptor agonist, cleared it at both doses (risk ratios 2.56 and 3.07). Survodutide 6 mg cleared it at 7.25 (95% CI 2.07 to 25.36). Tirzepatide cleared it at all three doses, from 4.29 to 6.00. That grouping is the finding worth carrying, and it sits alongside the organ comparisons in the pooled kidney outcomes.
Two of the six are not things a reader can buy. Survodutide, which tops the table, is investigational and not approved anywhere — the mediation analysis of its liver effects is on this site’s sister publication. Tirzepatide is available but not licensed for this indication in most places, so obtaining it for a liver reason means an off-label conversation.
Resmetirom deserves its own note precisely because it is not in this drug class. A reader arriving here with a liver diagnosis should know one thing first. The drug approved for their condition works through a different mechanism. It appears in this analysis with the narrowest confidence intervals of the six — 1.09 to 6.02 and 1.31 to 7.16, still wide but less so than the rest.
The practical translation is that several things work and nobody can yet say which works best. That is more useful than a ranking. It points the decision back to cost, route, tolerability and what a prescriber will actually write — the factors weighed in is a GLP-1 worth what it costs and the MASH screening analysis.